Education
About Us
Working with TipRanks
Follow Us
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
Total Valuation
ImmunoCellular Therapeutics has a market cap or net worth of $15.72M. The enterprise value is ―.
Market Cap$15.72M
Enterprise Value―
Share Statistics
ImmunoCellular Therapeutics has 113,270,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,270,750
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmunoCellular Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-537.58K
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmunoCellular Therapeutics is -16.29. ImmunoCellular Therapeutics’s PEG ratio is 0.41.
PE Ratio-16.29
PS Ratio―
PB Ratio-4.62
Price to Fair Value-4.62
Price to FCF-18.48
Price to Operating Cash Flow-18.48
PEG Ratio0.41
Income Statement
In the last 12 months, ImmunoCellular Therapeutics had revenue of 0.00 and earned -1.61M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit0.00
Operating Income-1.82M
Pretax Income-1.61M
Net Income-1.61M
EBITDA-1.06M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -687.93K and capital expenditures 0.00, giving a free cash flow of -687.93K billion.
Operating Cash Flow-687.93K
Free Cash Flow-687.93K
Free Cash Flow per Share>-0.01
Dividends & Yields
ImmunoCellular Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-22.22%
50-Day Moving Average0.15
200-Day Moving Average0.14
Relative Strength Index (RSI)46.82
Average Volume (3m)6.31K
Important Dates
ImmunoCellular Therapeutics upcoming earnings date is Aug 13, 2018, TBA Not Confirmed.
Last Earnings DateInvalid Date
Next Earnings DateAug 13, 2018
Ex-Dividend Date―
Financial Position
ImmunoCellular Therapeutics as a current ratio of 0.07, with Debt / Equity ratio of -83.18%
Current Ratio0.07
Quick Ratio0.07
Debt to Market Cap0.18
Net Debt to EBITDA―
Interest Coverage Ratio-3.30
Taxes
In the past 12 months, ImmunoCellular Therapeutics has paid -167.90K in taxes.
Income Tax-167.90K
Effective Tax Rate0.10
Enterprise Valuation
ImmunoCellular Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
ImmunoCellular Therapeutics has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $0.00 billion.
Cash & Marketable Securities$0.00
Total Debt$0.00
Net Cash$0.00
Net Cash Per Share$0.00
Tangible Book Value Per Share-$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ImmunoCellular Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―